SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0000950123-11-015543
Filing Date
2011-02-18
Accepted
2011-02-18 12:39:09
Documents
3
Group Members
ANSBERT GADICKEASHLEY DOMBKOWSKIJAMES PAUL SCOPAJOHN VANDER VORTLUKE EVNINMPM ASSET MANAGEMENT INVESTORS BV4 LLCMPM BIOVENTURES IV GMBH & CO. BETEILIGUNGS KGMPM BIOVENTURES IV GP LLCMPM BIOVENTURES IV LLCMPM BIOVENTURES IV Q-P, L.P.STEVEN ST. PETERVAUGHN

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D c12862sc13d.htm SC 13D 253412
2 EXHIBIT B c12862exv99wb.htm EX-99.B 12824
3 EXHIBIT C c12862exv99wc.htm EX-99.C 11932
  Complete submission text file 0000950123-11-015543.txt   280749
Mailing Address 200 CLARENDON STREET, 54TH FLOOR BOSTON MA 02116
Business Address 200 CLARENDON STREET, 54TH FLOOR BOSTON MA 02116 617-425-9200
MPM BioVentures IV QP LP (Filed by) CIK: 0001358309 (see all company filings)

IRS No.: 204217788 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D

Mailing Address 5 SYLVAN WAY SUITE 125 PARSIPPANY NJ 07054
Business Address 5 SYLVAN WAY SUITE 125 PARSIPPANY NJ 07054 973-254-3560
Pacira Pharmaceuticals, Inc. (Subject) CIK: 0001396814 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-86096 | Film No.: 11623560
SIC: 2834 Pharmaceutical Preparations